Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?

Cetinkaya, Mehmet; DELİKTAŞ, Hasan; ŞAHİN, Hayrettin

Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?

Hayrettin ŞAHİN, (Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Muğla, Türkiye)

Mehmet ÇETİNKAYA, (Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Muğla, Türkiye)

Hasan DELİKTAŞ (Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Muğla, Türkiye)

Üroonkoloji Bülteni

7 1

Yıl: 2017 Cilt: 16 Sayı: 3 Sayfa Aralığı: 95 - 100 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?

Öz:

Günümüzde prostat kanseri için kabul edilen tarama araçları prostat spesifik antijen (PSA) ve rektal incelemedir. PSA, prostata spesifik; ancak kansere spesifik değildir. Bu nedenle tek başına serum PSA ölçümünün prostat kanseri tanısındaki özgüllüğü düşük olup, yanlış pozitif sonuçlara ve gereksiz biyopsilere de yol açabilir. Bu sorunlar nedeniyle son yıllarda PSA'nın etkinliğini arttırmak ve/veya daha etkin yeni tümör belirteçleri bulabilmek için çalışılmaktadır. Ancak, prostat kanserinin heterojenik özelliği nedeniyle tek bir belirtecin istenilen faydayı sağlaması mümkün görünmemektedir. Bu nedenle son yıllarda belirteçlerin kombine kullanımı gündeme gelmiş ve böylece daha yüksek duyarlılık ve özgüllük oranları elde edilmiştir

Anahtar Kelime:

Konular: Üroloji ve Nefroloji Onkoloji

What are the New Developments in Urinary, Serum and Tissue Biomarkers in Prostate Cancer?

Öz:

Currently the accepted screening tools for prostate cancer are prostate specific antigen (PSA) and rectal examination. PSA is specific to prostate, but not to prostate cancer. Therefore, identifying prostate cancer only by serum PSA measurement has low specificity and may lead to false positive results and unnecessary biopsies. Due to these problems, it is investigated to increase the effectiveness of PSA and/or to find new biomarkers. However, it does not seem possible to have the adequate benefit from only one biomarker due to heterogeneous feature of prostate cancer. Therefore, in the recent years, combined use of biomarkers became a current issue and higher sensitivity and specificity rates were established

Anahtar Kelime:

Konular: Üroloji ve Nefroloji Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
3. Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: an update. Urol Oncol 2014;32:252-260.
4. Tefekli AH. Prostat kanserinde yeni belirteçler ve Phi skoru. Turk Urol Sem 2012;3:61-69.
5. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol 2013;5:318-329.
6. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2013;112:717-728.
7. Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) 2016;39:97-106.
8. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650-1655.
9. Sartori DA, Chan DW. Biomarkers in prostate cancer: what’s new? Curr Opin Oncol 2014;26:259-264.
10. Lazzeri M, Abrate A. Lughezzani G, et al. Relationship of chronic histologic prostatic infamation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 2014;83:606-612.
11. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
12. Getzenberg RH, Partin AW. Prostate cancer tumor markers. In: Kavoussi LR, Novick AC, Partin AW and Peters CA, eds. CampbellWalsh Urology. 2012;98:2748-2762.
13. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-1095.
14. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-1592.
15. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012;187:795-801.
16. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6:255-261.
17. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
18. Auprich M, Bjartell A, Chun FK, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011;60:1045-1054.
19. Kervancıoğlu E, Koşan M. Prostat kanseri doku ve serum biyomarkerlarında güncel durum değerlendirilmesi. Bull Urooncol 2015;14:102-107.
20. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
21. Kurek R, Nunez G, Tselis N, et al. Prognostic value of combined “triple”-reverse transcription-PCR analysis for prostatespecific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004;10:5808-5814.
22. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-2226.
23. Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004;96:834-843.
24. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-1404.
25. Jiang Z, Woda BA. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 2004;11:316-321.
26. Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95:1634-1637.
27. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, et al. Methylationspecific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci 2008;1137:222-225.
28. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-4043.
29. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309.
30. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of Circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009;15:2091-2097.
31. Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011;50(Suppl 1):85-89.
32. Murphy GP, Holmes EH, Boynton AL, et al. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaPbased enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995;26:164-168.
33. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701.
34. Shariat SF, Semjonow A, Lilja H, et al. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011;50(Suppl 1):61-75.
35. Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-355.
36. Al-Janabi O, Taubert H, Lohse-Fischer A, et al. Association of Tissue mRNA and Serum Antigen Levels of Members of the UrokinaseType Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer. Biomed Res Int 2014;2014:972587.
37. Fujita K, Ewing CM, Chan DY, et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 2009;124:664-669.
38. Karzai FH, Apolo AB, Cao L, et al. A phase I study of TRC 105 antiendoglin (CD105) antibody in metastatic castration-resistant prostate cancer. BJU Int 2015;116:546-555.
39. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-685.
40. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-3579.
41. Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta (1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-9.
42. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 2016;70:45-53.
43. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013;31:566-571.
44. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013;14:690.
45. Blume-Jensen P, Berman DM, Rimm DL, M. et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 2015;21:2591-2600.
46. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-1434.
47. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression Signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-1099.
48. Parr RL, Mills J, Harbottle A, et al. Mitochondria, prostate cancer, and biopsy sampling error. Discov Med 2013;15:213-220.
49. Carlsson S, Maschino A, Schröder F, et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol 2013;64:693-699.
50. Badani K, Thompson DJ, Buerki C, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013;4:600-609.
51. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology (Williston Park) 2014;28:135-142.

APA	ŞAHİN H, Cetinkaya M, DELİKTAŞ H (2017). Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. , 95 - 100.
Chicago	ŞAHİN Hayrettin,Cetinkaya Mehmet,DELİKTAŞ Hasan Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. (2017): 95 - 100.
MLA	ŞAHİN Hayrettin,Cetinkaya Mehmet,DELİKTAŞ Hasan Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. , 2017, ss.95 - 100.
AMA	ŞAHİN H,Cetinkaya M,DELİKTAŞ H Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. . 2017; 95 - 100.
Vancouver	ŞAHİN H,Cetinkaya M,DELİKTAŞ H Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. . 2017; 95 - 100.
IEEE	ŞAHİN H,Cetinkaya M,DELİKTAŞ H "Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?." , ss.95 - 100, 2017.
ISNAD	ŞAHİN, Hayrettin vd. "Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?". (2017), 95-100.

APA	ŞAHİN H, Cetinkaya M, DELİKTAŞ H (2017). Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. Üroonkoloji Bülteni, 16(3), 95 - 100.
Chicago	ŞAHİN Hayrettin,Cetinkaya Mehmet,DELİKTAŞ Hasan Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. Üroonkoloji Bülteni 16, no.3 (2017): 95 - 100.
MLA	ŞAHİN Hayrettin,Cetinkaya Mehmet,DELİKTAŞ Hasan Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. Üroonkoloji Bülteni, vol.16, no.3, 2017, ss.95 - 100.
AMA	ŞAHİN H,Cetinkaya M,DELİKTAŞ H Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. Üroonkoloji Bülteni. 2017; 16(3): 95 - 100.
Vancouver	ŞAHİN H,Cetinkaya M,DELİKTAŞ H Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?. Üroonkoloji Bülteni. 2017; 16(3): 95 - 100.
IEEE	ŞAHİN H,Cetinkaya M,DELİKTAŞ H "Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?." Üroonkoloji Bülteni, 16, ss.95 - 100, 2017.
ISNAD	ŞAHİN, Hayrettin vd. "Prostat Kanserinde; Üriner, Serum ve Doku Biyomarkerlerinde Yeni Gelişmeler Nelerdir?". Üroonkoloji Bülteni 16/3 (2017), 95-100.